Pulmonx Q4 revenue beats expectations

Pulmonx

04/03/2026 21:18

Overview

Lung disease treatment firm's Q4 total worldwide revenue fell 5% yr/yr but beat analyst expectations

Adjusted EBITDA loss for Q4 narrowed compared to last year

Company refinanced debt with a new $60 mln credit facility extending to 2031

Outlook

Pulmonx expects 2026 revenue between $90 mln and $92 mln

Company anticipates 2026 gross margin to be approximately 75%

Pulmonx projects 2026 operating expenses between $113 mln and $115 mln

Result Drivers

INTERNATIONAL GROWTH - International revenue increased by 8% in Q4 2025, offsetting some of the decline in U.S. revenue

COST RESTRUCTURING - Pulmonx reduced operating expenses by 11% in Q4 2025 through a cost restructuring initiative

Company press release: ID:nGNXdwms1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Total Worldwide Revenue
Beat
$22.60 mln
$21.73 mln (6 Analysts)
Q4 EPS
-$0.25
Q4 Net Income
-$10.43 mln
Q4 Gross Profit
$17.54 mln
Q4 Income From Operations
-$9.90 mln
Q4 Pretax Profit
-$10.24 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Pulmonx Corp is $4.50, about 194.1% above its March 3 closing price of $1.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)